The combine dosage form of Sofosbuvir (SFB) and Ledipasvir (LDV) used in the treatment of Hepatitis C virus genotype 1 infection. A simple,accurate and subsequent stability indicating HPLC and HPTLC methods for simultaneous estimation of SFB and LDV in their combined formulation was developed and validated as per the guidelines given by International Conference on Harmonization In HPTLC, separations was achieved on aluminium plate precoated with silica gel 60 F254 using toluene:methanol:ethyl acetate: acetic acid (6 : 2 : 2 : 0.3, V/V/V/V) as mobile phase. The compact bands of SFB and LDV at 0.53 ± 0.01 and 0.37 ± 0.02 respectively were scanned at 254 nm. In RP-HPLC separation was achieved on Agilent 1260,binary pump , with C18 (250 cm × 4.6 mm) 5 µm column. The mobile phase composition of Phosphate buffer pH 2.5 : Acetonitrile: Methanol (60:30:10 (V/V/V) used for development with flow rate of 1.5 ml/min maintained at an room temperature. The retention time obtained for LDV and SFB were at 3.144 min and 5.732 min respectively. In HPTLC Linear regression analysis revealed linearity in the range of 1000 to 6000ng/spot for SFB and 100 to 600 ng/spot for LDV respectively. The standard solution in diluent was prepared and scanned in the UV range. Quantification was achieved with ultraviolet detection at 254 nm based on the overlay UV spectrum . For both the methods, dosage form was exposed to acid, alkali oxidative, dry heat and photolytic stress. The degradation products, shows well resolved peaks with significantly different retention time value in HPLC and with significantly different retention factor in HPTLC.The methods distinctly separated the drugs and degradation products even in actual samples. Hence the proposed methods are, precise, accurate for routine quantification of SFB and LDV in tablet formulation.